Illumina's Low-Cost MiSeq Promises to Speed up Next-Gen Sequencing

The company expects that MiSeq will be used in the clinic. "We think it's ideally suited, from an output and a turnaround time and a design perspective, to be used in clinical applications, and we think that's a very large emerging market," CEO Jay Flatley said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.